Copper Histidinate
Menkes Disease
Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Menkes Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Droxidopa Stephen G. Kaler | Phase 1/2 | CCC |
Copper Histidine Cyprium Therapeutics, Inc. | Phase 3 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →